Vancouver, BC – July 27, 2017 - InMed Pharmaceuticals, Inc. (“InMed” or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today the publication of company-sponsored research in the European Journal of Pain. The article, titled “Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation”, presents results from a study co-sponsored by InMed and the MITACS Elevate Postdoctoral Fellowship program. The study was conducted by Dr. Hayes Wong and Prof. Brian Cairns at the University of British Columbia and was co-authored by Dr. Sazzad Hossain, Chief Scientific Officer of InMed.
The study results suggest that peripheral application of cannabinoids targeting the natural endocannabinoid receptor system (in this case, receptor CB1) may provide a valuable approach in treating severe pain. The model utilized in this study mimics muscle pain reported by sufferers of temporomandibular disorders (TMD) that affect the jaw muscles and joint. TMD is a chronic pain condition that is difficult to treat with current pain-relieving medications and more commonly affects women than men.
“Developing a topically-applied product that can provide localized relief of chronic and/or acute severe pain, without central side effects, remains one of the ‘holy grails’ in the field of analgesia”, said Dr. Sazzad Hossain, CSO of InMed. “This study sets the stage for advanced work in various pain models to explore the role of several cannabinoid compounds, applied as topical agents, to target the CB1 and other pain-related receptors.”
Use of InMed’s proprietary bioinformatics database assessment tool has led to the identification of several individual cannabinoid compounds, or combinations thereof, to specifically address both chronic and acute pain in a topically-applied product. “InMed’s internal targeting capabilities, linking specific cannabinoids to diseases with a high unmet medical need, remains a fundamental component to our ongoing success in validating the role of this class of compounds in a wide range of diseases”, added Dr. Hossain.
For additional information, please follow this link to the article: http://onlinelibrary.wiley.com/doi/10.1002/ejp.1085/full
Mitacs Elevate helps organizations develop their research & development management capacity in-house with a minimal impact on their R&D budgets. By connecting companies with a talented PhD graduates, the two-year research project encourages knowledge transfer of the fellow’s practical and professional skills to the organization. These collaborations help build research and development management capacity and companies benefit from fellows’ creativity and fresh approach to current research challenges.
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
Contact: InMed Pharmaceuticals Inc .
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: that peripheral or topical application of cannabinoids targeting the natural endocannabinoid receptor system (in this case, receptor CB1) provides a valuable approach in treating chronic and/or acute severe pain without central side effects, InMed’s proprietary bioinformatics database assessment tool, linking specific cannabinoids to diseases with a high unmet medical need, being able to validate the role of this class of compounds in a wide range of diseases, and the expected fundamental value drivers of the Company.
With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: that peripheral or topical application of cannabinoids, identified by InMed’s proprietary bioinformatics database assessment tool, will be able to effectively target the natural endocannabinoid receptor system (in this case, receptor CB1) which will provide a valuable approach in treating chronic and/or acute severe pain without central side effects; InMed’s proprietary platform technology, product pipeline and drug development programs may not return their expected level of value.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com . In addition, readers should review the disclosure under the heading “Risk Factors” in the Final Prospectus, once filed. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.